Abstract
2PD Monitoring of secondary drug resistance mutations in circulating tumor DNA of patients with advanced ALK positive NSCLC
Full Text
Sign-in/Register to access full text options
Published version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have